查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1666173

全球储存自体血输血市场 - 2025 至 2033 年

Global Stored Autologous Blood Transfusion Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年全球储存自体血输血市场规模达到 1,498 亿美元，预计到 2033 年将达到 1,823 亿美元，2025-2033 年预测期内的复合年增长率为 2.5%。

储存自体血输血是指患者在预定的手术或医疗程序之前捐献血液，然后将该血液储存起来以备将来在手术期间或手术后使用的过程。自体输血的主要特征是捐赠者和受赠者是同一个人。这消除了与异体（捐赠者）输血相关的风险，例如输血反应、感染和免疫併发症。

患者在计划手术前几天或几週捐血，通常是在医院或临床环境中，采集的血液经过处理后储存在血库中，在血库中使用抗凝剂保存以维持其活力（如果需要），储存的血液在手术或恢復期间取出并重新输入患者体内，这通常用于控製手术过程中的失血，如果患者在手术后失血的结果恢復结果。储存的自体血可以减轻对外部捐血者的依赖，特别是在预计会失血的手术中。

市场动态：

驱动因素与约束因素

手术量和高风险手术的成长

手术量和高风险手术的成长极大地推动了储存自体血输血市场的成长，并有望在预测期内透过增加对安全高效的血液管理系统的需求来推动市场的发展。高风险手术通常会造成大量失血，而自体输血被认为是比异体输血更安全、更可靠的替代方案。

在经常大量失血的脊椎手术中，最好使用储存的自体血，因为它可以消除输血相关感染和免疫反应的风险，这些风险对于高风险患者来说可能危及生命。

例如，根据美国国立卫生研究院 (NIH) 的数据，全球估计每年进行近 3.13 亿例手术，其中美国每年进行约 50 万例腰椎手术。高达 80% 的脊椎手术患者会经历术后不适，20% 的患者会经历持续的术后疼痛。每年约有 90 万名美国成年人和 3 万名加拿大成年人接受脊椎手术。脊椎手术的增加可能会增加失血过多的风险，这进一步增加了对储存自体血输血装置的需求，用于在手术前储存血液并在手术中输入患者的血液。

在某些手术中的适用性有限

预计在某些手术中的适用性有限将阻碍储存自体血输血市场的成长。虽然自体血输注对许多高风险手术非常有益，但它并不适用于所有类型的手术或不切实际。多种因素导致其适用性有限，从而限制了市场的成长潜力。

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动态

  • 影响因素
    • 驱动程式
      • 手术量和高风险手术的成长
    • 限制
      • 在某些手术中的适用性有限
    • 机会
  • 影响分析

第五章：战略洞察与产业展望

  • 市场领导者和先驱者
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的成熟领导者
    • 拥有成熟产品的市场领导者
  • CXO 观点
  • 最新进展与突破
  • 案例研究/正在进行的研究
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT 分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态
  • 关键意见领袖

第 6 章：依产品类型

  • 血液采集设备
  • 输血套件
  • 血液处理产品
  • 血液储存设备

第 7 章：按应用

  • 骨科手术
  • 一般外科手术
  • 妇产科手术
  • 其他的

第 8 章：按储存期限

  • 短期储存
  • 长期储存

第 9 章：按技术

  • 手动采血
  • 自动采血

第 10 章：按最终用户

  • 血库
  • 医院
  • 门诊手术中心

第 11 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 12 章：竞争格局

  • 竞争格局
  • 市场定位/份额分析
  • 併购分析

第 13 章：公司简介

  • Terumo Corporation
    • 公司概况
    • 产品组合
      • 产品描述
      • 产品关键绩效指标 (KPI)
      • 历史和预测产品销售量
      • 产品销售量
    • 财务概览
      • 公司收入
      • 地区收入份额
      • 收入预测
    • 主要进展
      • 合併与收购
      • 关键产品开发活动
      • 监管部门批准等
    • SWOT 分析
  • Haemonetics Corporation
  • Medtronic
  • JMS Co. Ltd.
  • Narang Medical Limited.
  • Becton, Dickinson and Company
  • Fresenius Kabi AG
  • Nipro
  • Macopharma
  • Cardinal Health
  • Similar data will be provided for each market player.

第 14 章：附录

简介目录
Product Code: MD9190

The global stored autologous blood transfusion market reached US$ 149.8 billion in 2024 and is expected to reach US$ 182.3 billion by 2033, growing at a CAGR of 2.5% during the forecast period 2025-2033.

Stored autologous blood transfusion refers to the process in which a patient donates their blood before a scheduled surgery or medical procedure, and this blood is then stored for future use during or after the procedure if needed. The key characteristic of autologous transfusion is that the donor and the recipient are the same individual. This eliminates the risks associated with allogeneic (donor) blood transfusions, such as transfusion reactions, infections, and immune complications.

The patient donates blood several days or weeks before planned surgery, typically in a hospital or clinical setting, the collected blood is processed and stored in blood banks, where it is preserved using anticoagulants to maintain its viability if needed, the stored blood is retrieved and reinfused into the patient during surgery or recovery, this is typically used to manage blood loss during the procedure if the patient experiences excessive blood loss after surgery, the stored blood can be reinfused to replenish lost blood volumes and improve recovery outcomes. Stored autologous blood can alleviate reliance on external blood donors, particularly in surgeries where blood loss is anticipated.

Market Dynamics: Drivers & Restraints

Growth in Surgical Volume and High-Risk Procedures

The growth in surgical volume and high-risk procedures is significantly driving the growth of the stored autologous blood transfusion market and is expected to drive the market over the forecast period by increasing the demand for safe and efficient blood management systems. High-risk surgeries often involve significant blood loss and autologous blood transfusion is considered a safer and more reliable alternative to allogeneic blood transfusions.

In spinal surgeries where large blood losses are common, using stored autologous blood is preferred because it eliminates the risk of transfusion-related infections and immunological reactions, which can be life-threatening in high-risk patients.

For instance, according to the National Institute of Health (NIH), global estimates suggest that close to 313 million surgeries are performed annually with approximately 500,000 lumbar spine surgeries each year in the United States. Up to 80% of spine surgery patients experience post-surgery discomfort and 20% will experience persistent post-surgical pain. Approximately 900,000 American and 30,000 Canadian adults undergo spine surgery annually. These rising spinal surgeries may increase the risk of excessive blood loss, which further boosts the demand for stored autologous blood transfusion devices to store the blood before surgery and to transfuse the patient's blood for such surgery.

Limited Applicability in Certain Surgeries

Limited applicability in certain surgeries is expected to hamper the growth of the stored autologous blood transfusion market. While autologous blood transfusion is highly beneficial in many high-risk surgeries, it is not suitable or practical in all types of surgeries. Several factors contribute to its limited applicability, and this restricts the market's growth potential.

Segment Analysis

The global stored autologous blood transfusion market is segmented based on product type, application, storage duration, technology, end-user, and region.

Product Type:

Blood collection devices segment is expected to dominate the global stored autologous blood transfusion market share

Blood collection devices are medical tools used in healthcare settings like hospitals, diagnostic laboratories, and blood donation centers for safe and efficient collection, storage, and transportation of blood samples. These devices, including syringes, vacuum-based tubes, capillary systems, lancets, needles, and blood bags, ensure minimal discomfort for patients, prevent contamination, and maintain sample integrity for accurate diagnostic testing or transfusion purposes.

The blood collection devices segment is driving the global stored autologous blood transfusion market due to the significant product launches, demand for safe and efficient methods, technological advancements, and minimally invasive procedures. Moreover, the rise in surgeries requiring autologous blood transfusions and increased awareness about allogeneic blood transfusion risks have increased the need for advanced devices further fueling this segment's growth.

For instance, in March 2024, BD has launched the BD Vacutainer UltraTouch Push Button Blood Collection Set in India to reduce patient pain and discomfort during blood collection. The set uses BD RightGauge technology, a thinner needle, and BD PentaPoint Technology, resulting in a significant decrease in insertion pain. The BD Push Button Technology reduces needle injury chances by 88%. The set is designed to minimize the need for needles during blood collection.

Moreover, in October 2024, Ahlstrom launched Lipid Saver, a new solution for collecting, transporting, and storing fatty acids from whole blood samples. The innovative specimen collection card allows for easy, reliable, and long-term preservation of saturated and unsaturated fatty acids at room temperature.

Geographical Analysis

North America is expected to hold a significant position in the global stored autologous blood transfusion market share

North America dominates the global stored autologous blood transfusion market due to high surgical volumes. The increased awareness of transfusion-related risks, regulatory frameworks in the US, technological advancements in blood collection and storage devices, and leading market players contribute to North America's dominance.

Furthermore, the launch of new products and advancements in the region help the region to grow during the forecast period. For instance, in October 2024, Terumo Blood and Cell Technologies (Terumo BCT) has introduced the Reveos Automated Blood Processing System in the US, aiming to streamline the whole blood processing process and improve efficiency. The system will be used by Carter BloodCare in Texas to manufacture platelets, red blood cells, and plasma for transfusion.

Moreover, according to the Leukemia & Lymphoma Society, about every 3 minutes, a person in the US is diagnosed with either leukemia, lymphoma, or myeloma. In the year 2024, the overall projected case of leukemia, lymphoma, or myeloma in the US is 187,740. New incidences of leukemia, lymphoma and myeloma cases will represent 9.4% of the new cancer cases projected for diagnosis in the US in the year 2024 which will be 2,001,140 cases. Thus, the above factors contribute to the region's dominance in the global market.

Competitive Landscape

The major global players in the stored autologous blood transfusion market include Terumo Corporation, Haemonetics Corporation, Medtronic, JMS Co. Ltd., Narang Medical Limited., Becton, Dickinson and Company, Fresenius Kabi AG, Nipro, Macopharma and Cardinal Health among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Stored Autologous Blood Transfusion Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by Storage Duration
  • 3.4. Snippet by Technology
  • 3.5. Snippet by End User
  • 3.6. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growth in Surgical Volume and High-Risk Procedures
    • 4.1.2. Restraints
      • 4.1.2.1. Limited Applicability in Certain Surgeries
    • 4.1.3. Opportunity
  • 4.2. Impact Analysis

5. Strategic Insights and Industry Outlook

  • 5.1. Market Leaders and Pioneers
    • 5.1.1. Emerging Pioneers and Prominent Players
    • 5.1.2. Established leaders with largest selling Brand
    • 5.1.3. Market leaders with established Product
  • 5.2. CXO Perspectives
  • 5.3. Latest Developments and Breakthroughs
  • 5.4. Case Studies/Ongoing Research
  • 5.5. Regulatory and Reimbursement Landscape
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa
  • 5.6. Porter's Five Force Analysis
  • 5.7. Supply Chain Analysis
  • 5.8. Patent Analysis
  • 5.9. SWOT Analysis
  • 5.10. Unmet Needs and Gaps
  • 5.11. Recommended Strategies for Market Entry and Expansion
  • 5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 5.13. Pricing Analysis and Price Dynamics
  • 5.14. Key Opinion Leaders

6. By Product Type

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. Blood Collection Devices*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Blood Transfusion Kits
  • 6.4. Blood Processing Products
  • 6.5. Blood Storage Devices

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Orthopedic Surgeries*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. General Surgeries
  • 7.4. Obstetrics & Gynecology Surgeries
  • 7.5. Others

8. By Storage Duration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Storage Duration
    • 8.1.2. Market Attractiveness Index, By Storage Duration
  • 8.2. Short-Term Storage*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Long-Term Storage

9. By Technology

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 9.1.2. Market Attractiveness Index, By Technology
  • 9.2. Manual Blood Collection*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Automated Blood Collection

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Blood Banks*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Hospitals
  • 10.4. Ambulatory Surgical Centers

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Storage Duration
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.8.1. U.S.
      • 11.2.8.2. Canada
      • 11.2.8.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Storage Duration
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.8.1. Germany
      • 11.3.8.2. U.K.
      • 11.3.8.3. France
      • 11.3.8.4. Spain
      • 11.3.8.5. Italy
      • 11.3.8.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Storage Duration
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.8.1. Brazil
      • 11.4.8.2. Argentina
      • 11.4.8.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Storage Duration
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.8.1. China
      • 11.5.8.2. India
      • 11.5.8.3. Japan
      • 11.5.8.4. South Korea
      • 11.5.8.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Storage Duration
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

Key Market Players

  • 13.1. Terumo Corporation*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio
      • 13.1.2.1. Product Description
      • 13.1.2.2. Product Key Performance Indicators (KPIs)
      • 13.1.2.3. Historic and Forecasted Product Sales
      • 13.1.2.4. Product Sales Volume
    • 13.1.3. Financial Overview
      • 13.1.3.1. Company Revenue's
      • 13.1.3.2. Geographical Revenue Shares
      • 13.1.3.3. Revenue Forecasts
    • 13.1.4. Key Developments
      • 13.1.4.1. Mergers & Acquisitions
      • 13.1.4.2. Key Product Development Activities
      • 13.1.4.3. Regulatory Approvals etc.
    • 13.1.5. SWOT Analysis
  • 13.2. Haemonetics Corporation
  • 13.3. Medtronic
  • 13.4. JMS Co. Ltd.
  • 13.5. Narang Medical Limited.
  • 13.6. Becton, Dickinson and Company
  • 13.7. Fresenius Kabi AG
  • 13.8. Nipro
  • 13.9. Macopharma
  • 13.10. Cardinal Health
  • Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us